A puzzling update from Novo Nordisk and new data from Roche at #ADA25news2025-06-21T14:53:07+00:00June 21st, 2025|Endpoints News|
#ADA25: Vertex’s diabetes cell therapy allows 10 patients to come off insulinnews2025-06-20T23:15:41+00:00June 20th, 2025|Endpoints News|
FDA to biotech CEOs: US is lagging behind on early-stage trialsnews2025-06-20T18:13:32+00:00June 20th, 2025|Endpoints News|
Zealand study shows higher GLP-1/GLP-2 doses may lead to greater weight lossnews2025-06-18T18:17:50+00:00June 18th, 2025|Endpoints News|
BIO’s new chair on FDA changes, most favored nation pricing and Chinanews2025-06-18T16:19:09+00:00June 18th, 2025|Endpoints News|
BioNTech drops indications, stops making cell therapy at Maryland sitenews2025-06-18T15:25:03+00:00June 18th, 2025|Endpoints News|
A custom ALS drug could help scale rare disease therapiesnews2025-06-18T15:00:06+00:00June 18th, 2025|Endpoints News|
Scholar Rock reports competitive data for muscle-preserving obesity drug add-onnews2025-06-18T14:44:12+00:00June 18th, 2025|Endpoints News|
Lyell’s lymphoma data for recently acquired CAR-T receive lukewarm reception on Wall Streetnews2025-06-17T15:29:21+00:00June 17th, 2025|Endpoints News|
Mineralys’ lorundrostat gets a Phase 2 win in certain patients with hypertensionnews2025-06-17T14:56:32+00:00June 17th, 2025|Endpoints News|
